Baird Upgrades Amylyx Pharmaceuticals(AMLX.US) to Buy Rating, Raises Target Price to $11
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Amylyx Pharmaceuticals Raised to Outperform From Neutral by Baird
Strong Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising Avexitide Prospects and Stable Financial Standing
Cautious Hold on Amylyx Pharmaceuticals Amid Uncertainty in Pipeline Progress
